Contents:

1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Executive Summary 2.2 Definitions 3 Overview 3.1 Background 4 Market Sizing 4.1 Market Revenues 4.2 Market Volumes 4.3 Cross Country Analysis 5 Market Dynamics 5.1 Market Drivers 5.2 Market Restraints 5.3 Present and Emerging Trends 5.3.1 Technological Advances 5.3.2 Competitive Technologies 5.3.3 Cardiopulmonary Stress Testing Scores over Cardiac Stress Testing 5.3.4 Difference of Opinions in the Cardiac and Respiratory Settings 5.3.5 Increasing Number of Indications for CPST 5.3.6 Cardiovascular Diseases (CVD) and Respiratory Diseases Epi-Centered Around the Developing World 5.3.7 Treadmill to Cycle 6 Competitive Landscape 6.1 Key Deals 7 Overview of Key Companies 7.1 GE Healthcare 7.1.1 Company Overview 7.2 Philips Healthcare 7.2.1 Company Overview 7.2.2 Value Chain Analysis 7.2.2.1 Manufacturing 7.2.2.2 Product Development 7.2.2.3 Sales and Marketing 7.2.3 Philips Medical Systems Pipeline Products 7.3 Cardiac Science Corporation 7.3.1 Company Overview 7.3.2 Value Chain Analysis 7.3.2.1 Manufacturing 7.3.2.2 Product Development 7.3.2.3 Sales and Marketing 7.4 Cardinal Health 7.4.1 Company Overview 7.4.2 Value Chain Analysis 7.4.2.1 Manufacturing 7.4.2.2 Product Development 7.4.2.3 Sales and Marketing 7.5 Cosmed Medical 7.5.1 Company Overview 8 Future Outlook and Implications 9 Appendix 9.1 Methodology 9.1.1 Coverage 9.1.2 Secondary Research 9.1.3 Primary Research 9.1.4 Models 9.1.5 Forecasts 9.1.6 Expert Panels 9.2 Contact US 9.3 Disclaimer List of Tables Table 1: Cardiopulmonary Stress Test Systems, Revenue ($ m), Global, 2001 – 2008 Table 2: Cardiopulmonary Stress Test Systems, Revenue ($ m), Global, 2008 – 2015 Table 3: Cardiopulmonary Stress Test Systems, Volume (Units), Global, 2001 – 2008 Table 4: Cardiopulmonary Stress Test Systems, Volume (Units), Global, 2008 – 2015 Table 5: Cardiopulmonary Stress Testing Systems, Cross Country Analysis, 2008 Table 6: Cardinal Acquires Viasys, Deal Value Table 7: Cardinal Acquires Viasys, Deal Details Table 8: Philips Medical Systems Pipeline Products by Equipment Type List of Figures Figure 1: Cardiopulmonary Stress Test Systems, Revenue ($ m), Global, 2001 – 2015 Figure 2: Cardiopulmonary Stress Test Systems, Volume (Units), Global, 2001 – 2015 Figure 3: Cardiopulmonary Stress Testing Systems, Cross Country Analysis, 2008 Figure 4: Philips Medical Systems Value Chain Analysis Figure 5: Cardiac Science Corporation Value Chain Analysis Figure 6: Cardinal Health, Inc. Value Chain Analysis Figure 7: GlobalData Methodology

Summary:

This report finds that an increasing incidence of Cardiovascular Diseases (CVD), globally, will drive the growth of the Cardiopulmonary Stress Testing Systems (CPST) market. The emergence of CPST as a primary tool of diagnosis for both CVD and other respiratory disorders is expected to drive revenue growth and investor interests in the global CPST market. “Global Cardiopulmonary Stress Testing Systems Market Analysis and Forecasts to 2015”, highlights these trends that determine the future of this market. Increasing Incidence of CVD and Respiratory Disorders to Drive Growth An increasing incidence of cardiovascular disorders will drive growth in the CPST market. According to the World Health Organization, more than 16 million people die of Cardiovascular Diseases (CVD) every year around the world. These increasing deaths related to CVD need to be prevented through effective early diagnosis. CPST testing promises to do that. This demand for an effective diagnostic tool will drive volume sales of the CPST market. Increasing incidence of respiratory diseases is another driver for the growth of this market. The next decade is expected to see a multifold increase in the new cases diagnosed for respiratory disorders. CPST system manufacturers will need to ensure that CPST is opined as the primary tool of diagnosis for these diseases. The US Remains the Largest Contributor for the Global CPST Market The US remains the largest revenue generator within the global CPST systems market. The US market is expected to grow at a CAGR of 9.5% during 2008 – 2015, which is higher than the global average of 8.7%. This growth is primarily attributed to the fact that the awareness and use of compact new technologies in the US is relatively high. Italy, Spain and France are also expected to grow with similar growth due to increasing awareness of CPST advantages. Japan and Germany are expected to grow at CAGRs of 7.0% and 8.0% during 2008 – 2015. Increasing Number of Indications for Cardiopulmonary Stress Testing to Increase the Number of Procedures Over the last five years the number of indications for the prescription of a CPST test has almost tripled. A test that was preliminarily intended for assessment of cardiac or pulmonary function prior to a surgery is now being used as a diagnostic tool for more than 10 clinical symptoms. This rapid increase in the number of indications reinstates the fact that CPST testing is slowly turning from an assessment tool into that of a primary diagnostic method for all cardiac and respiratory disorders. This trend is expected to continue, catalyzed by the advancement of technology.

Companies Mentioned

- GE Healthcare - Philips Healthcare - Cardiac Science Corporation - Cardinal Health - Cosmed Medical